Biogen Inc., BIIB is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Biogen Inc., BIIB has a market cap of 65873.67. Since its IPO date on the 9/17/1991, Biogen Inc., BIIB performance year to date is -1.17%. Today Biogen Inc., BIIB has gained -1.29%, with a current price of 298.86.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 88.30%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 18.50%, with return on investment at 23.50%.
In terms of debt levels and profit levels, Biogen Inc., BIIB is seeing a long-term debt/equity of 0.54. While Total debt/equity is 0.54. With a profit margin of 34.00%, this is combined with a gross margin of 87.50%, and operating margin of 47.60%. Biogen Inc. ability to meet debt levels, with a current ratio of 3.2, while the quick ratio is 2.8.
For the last year Biogen Inc., BIIB has seen a EPS growth of 24.00%. A performance for the year of 5.55%. The 52-week high is -10.43%, and the 52-week low is 34.01%. The average volume for Biogen Inc., BIIB is 373061.
With a target price of 338.79, can Biogen Inc., BIIB reach this target? Looking at the value indicators of Biogen Inc., BIIB. Biogen Inc. has a P/E of 17.12 and a forward P/E of 14.54. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.92. Biogen Inc. also has a P/S and a P/B of 5.77 and 5.47 respectively. For P/cash, Biogen Inc. has a value of 15.26, while it is 20.23 for P/free cash flow.
At the current price of 298.86, Biogen Inc. has a dividend yield of *TBA. We see a return on equity of 36.00%.
Looking more long-term Biogen Inc., is projected to get an EPS growth for the next five years of 8.91%. In the short-term an EPS growth of 3.05% in the next year is forecasted. This is after a EPS growth of 24.00% for this year and for the last five years a 31.30% growth has been seen.